AP2014007413A0 - Stable dosage forms of arterolane and piperaquine - Google Patents

Stable dosage forms of arterolane and piperaquine

Info

Publication number
AP2014007413A0
AP2014007413A0 AP2014007413A AP2014007413A AP2014007413A0 AP 2014007413 A0 AP2014007413 A0 AP 2014007413A0 AP 2014007413 A AP2014007413 A AP 2014007413A AP 2014007413 A AP2014007413 A AP 2014007413A AP 2014007413 A0 AP2014007413 A0 AP 2014007413A0
Authority
AP
ARIPO
Prior art keywords
arterolane
piperaquine
dosage forms
stable dosage
stable
Prior art date
Application number
AP2014007413A
Other languages
English (en)
Other versions
AP3777A (fr
Inventor
Sumit Madan
Arno Appavoo Enose
Harish Kumar Madan
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/183,119 external-priority patent/US8664265B2/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AP2014007413A0 publication Critical patent/AP2014007413A0/xx
Application granted granted Critical
Publication of AP3777A publication Critical patent/AP3777A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AP2014007413A 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine AP2014007413A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/183,119 US8664265B2 (en) 2005-05-18 2011-07-14 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
IN2703DE2011 2011-09-19
IN2156DE2012 2012-07-12
PCT/IB2012/053614 WO2013008218A1 (fr) 2011-07-14 2012-07-13 Formes posologiques stables d'artérolane et de pipéraquine

Publications (2)

Publication Number Publication Date
AP2014007413A0 true AP2014007413A0 (en) 2014-02-28
AP3777A AP3777A (fr) 2016-08-31

Family

ID=47505579

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007413A AP2014007413A0 (en) 2011-07-14 2012-07-13 Stable dosage forms of arterolane and piperaquine

Country Status (10)

Country Link
EP (1) EP2731603A1 (fr)
JP (1) JP2014522856A (fr)
KR (1) KR20140053169A (fr)
CN (1) CN103930107A (fr)
AP (1) AP2014007413A0 (fr)
AU (1) AU2012282077A1 (fr)
CA (1) CA2850089A1 (fr)
EA (1) EA201490233A8 (fr)
MX (1) MX2014000463A (fr)
WO (1) WO2013008218A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014132226A1 (fr) 2013-02-28 2014-09-04 Ranbaxy Laboratories Limited Formulation dispersible stable de maléate d'artérolane et de pipéraquine et procédé de préparation de celle-ci
KR101698003B1 (ko) * 2016-06-20 2017-01-19 여오영 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
MX2020006055A (es) * 2017-12-12 2020-08-20 Intervet Int Bv Composiciones farmaceuticas implantables de isoxazolina y usos de las mismas.
EP4196115A1 (fr) * 2020-08-14 2023-06-21 Sun Pharmaceutical Industries Limited Médicament combiné à dose fixe pour le traitement du paludisme

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486199B1 (en) 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US6906205B2 (en) 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
ES2615458T3 (es) * 2005-05-18 2017-06-07 Sun Pharmaceutical Industries Limited Formas de dosificación estables de antimaláricos de espiro y dispiro 1,2,4 trioxolano
AP2525A (en) * 2006-05-17 2012-12-05 Ranbaxy Lab Ltd Antimarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative

Also Published As

Publication number Publication date
MX2014000463A (es) 2014-07-09
JP2014522856A (ja) 2014-09-08
KR20140053169A (ko) 2014-05-07
AU2012282077A1 (en) 2014-01-30
AP3777A (fr) 2016-08-31
CN103930107A (zh) 2014-07-16
EA201490233A8 (ru) 2015-01-30
WO2013008218A1 (fr) 2013-01-17
EP2731603A1 (fr) 2014-05-21
CA2850089A1 (fr) 2013-01-17
EA201490233A1 (ru) 2014-07-30

Similar Documents

Publication Publication Date Title
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2721031A4 (fr) Inhibiteurs à bromodomaine et leurs utilisations
EP2705039A4 (fr) Inhibiteurs de bromodomaines et leurs utilisations
EP2772483A4 (fr) Compose 4-aminocarbazole et son utilisation
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2739144A4 (fr) Composés et ses utilisations thérapeutiques
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
HK1199705A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2718283A4 (fr) Dérivé d'indazole et pyrrolopyridine et utilisation pharmaceutique de celui-ci
EP2852397A4 (fr) Variants d'huwentoxine iv et procédés d'utilisation
EP2709999A4 (fr) Composés de quinazoline-7-éther et méthodes d'utilisation
EP2688901A4 (fr) Inhibiteurs de 17ss-hsd1, 17ss-hsd3 et 17ss-hsd10
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2734513A4 (fr) Intermédiaire de médicaments à base de statines et sa préparation
AP2014007413A0 (en) Stable dosage forms of arterolane and piperaquine
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
ZA201307230B (en) Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma-glutamyl-l-tryptophan
EP2536688A4 (fr) Formes posologiques stables de levomilnacipran
HK1198127A1 (en) Stable dosage forms of arterolane and piperaquine
GB201104632D0 (en) Use of medicament
GB201112081D0 (en) Prodrugs of non-opioids and uses thereof